MedTrace Logo

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

NCT07399067 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-13

No results posted yet for this study

Summary

The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).

Conditions

Interventions

DRUG

IBI3002

IBI3002 will be administered subcutaneously at the assigned dose level and dosing interval.

DRUG

Placebo

Matched placebo will be administered subcutaneously at the same schedule as IBI3002.

DRUG

Dupilumab

Dupilumab 300mg Q2w, with a loading dose of 600mg, will be administered subcutaneously.

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-06
Primary Completion
2027-03-23
Completion
2027-05-27

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399067 on ClinicalTrials.gov